American Society of Hematology (ASH)

Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). Read More ›

The results of the Radius-X expanded treatment protocol showed a safety profile that was consistent with that previously described in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML). Read More ›

In a pooled analysis of 370 patients with relapsed/refractory mantle-cell lymphoma, treatment with ibrutinib for a median follow-up of 3.5 years resulted in 26% being progression-free and 45% still alive, with manageable toxicity. Read More ›

In this analysis, the hedgehog pathway inhibitor sonidegib plus azacitidine combination therapy showed encouraging antileukemia activity in terms of high rate of disease stabilization, particularly in the relapsed/refractory acute myeloid leukemia patient population. Read More ›

When used in first-cycle therapy for chronic lymphocytic leukemia (CLL), rates of resource utilization and total costs of care were significantly lower for ibrutinib than for chemotherapy or chemoimmunotherapy, with ibrutinib-treated patients having lower emergency department and inpatient costs per month and less frequent office and outpatient visits than patients treated with chemotherapy or chemoimmunotherapy. Read More ›

The initial results of a phase 1 study suggest that combination therapy with ivosidenib or enasidenib plus standard induction chemotherapy is well-tolerated and effective in newly diagnosed patients with IDH-mutated (mIDH), relapsed/refractory acute myeloid leukemia (AML). Read More ›

In patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (NHL), use of prophylactic tocilizumab may reduce the incidence of severe cytokine release syndrome but not neurologic events in patients treated with chimeric antigen receptor T-cell therapy. Read More ›

In this subanalysis of the AG221-C-001 phase 1 study, enasidenib monotherapy was found to be well-tolerated, and yielded hematologic responses in previously untreated older patients with IDH2-mutated (mIDH2) acute myeloid leukemia (AML) who are not fit to receive standard cytotoxic chemotherapy. Read More ›

Single-agent ibrutinib is associated with longer progression-free survival and a generally more favorable safety profile than chemoimmunotherapy in patients with treatment-naïve chronic lymphocytic leukemia (CLL). Read More ›

This analysis showed that ivosidenib-treated patients with IDH1-mutated (mIDH1), relapsed/refractory, and untreated acute myeloid leukemia (AML) whose best response is a complete remission (CR) or CR with partial hematologic recovery achieve mIDH1 clearance ≤0.04%. Read More ›